• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

    5/12/25 2:10:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Arcturus Therapeutics Holdings Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    03969T109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03969T109


    1Names of Reporting Persons

    Nikko Asset Management Americas, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,690,962.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,926,084.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,926,084.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arcturus Therapeutics Holdings Inc.
    (b)Address of issuer's principal executive offices:

    10628 Science Center Drive, Suite 250, San Diego, California, 92121
    Item 2. 
    (a)Name of person filing:

    Nikko Asset Management Americas, Inc.
    (b)Address or principal business office or, if none, residence:

    605 Third Avenue, 38th Floor, New York, NY 10158
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    03969T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,926,084
    (b)Percent of class:

    7.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,690,962

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,926,804

    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Exhibit A.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit A.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nikko Asset Management Americas, Inc.
     
    Signature:/s/ Gary L. Beckham
    Name/Title:Gary L. Beckham, Chief Compliance Officer
    Date:05/12/2025
    Get the next $ARCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    11/3/2022$22.00 → $35.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

      Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight

      5/12/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influ

      4/10/25 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Financials

    Live finance-specific insights

    See more
    • Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

      Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight

      5/12/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Kurata Lance

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:07:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Payne Joseph E

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:59 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer & COO Chivukula Pad

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:26 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

      10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:11:34 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:05:47 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      5/12/25 2:10:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

      2/4/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

      Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

      6/20/24 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Appoints John Markels, Ph.D. to its Board of Directors

      Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

      12/13/22 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/8/24 3:17:24 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/5/24 6:07:26 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/5/24 12:18:33 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Arcturus Therapeutics with a new price target

      BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00

      1/28/25 8:51:42 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Arcturus Therapeutics with a new price target

      Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00

      8/12/24 7:16:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Arcturus Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00

      12/13/23 8:02:48 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care